

DAFTAR PUSTAKA

1. Skeel RT, Kleif SN. Biologic and pharmacologic basis of cancer chemotherapy and biotherapy. In : Skeel RT. Handbook of cancer chemotherapy, 7th Ed. Philadelphia (USA): Lippincott Williams & Wilkins; 2007:p1-37
2. Nguyen DH, Colvin ME, Fink WH. The molecular aspect of anticancer drug: DNA interactions and its implication to drug design. Galley proof 2007;10:402-16
3. Kuttan G, Pratheeshkumar P. *Cardiospermum halicacabum* inhibits cyclophosphamide induced immunosuppression and oxidative stress in mice and also regulates iNOS and COX-2 gene expression in LPS stimulated macrophages. *Asian Pasific J Cancer Prev* 2010;11:1245-52
4. Sudigdo A. Penggunaan obat golongan immunosupresif dan sitotoksik pada penyakit kulit. *Media dermato-venereologica Indonesiana* 2009; 26:14-20
5. Arlen PL, Guley JL. Hematopoietic growth factors. In :Abraham J, Allegra CJ, Gulley J. Bethesda handbook of clinical oncology, 2nd ed. Philadelphia (USA): Lippincott Williams & Wilkins; 2005: p476-90
6. Priestman T. Some practical aspects of cancer chemotherapy. In : Priestman T. Cancer chemotherapy in clinical practice. Berlin: Springer Verlag; 2008:p35-77

7. Lalla RV, Pilbeam CC, Walsh SJ, Sonis ST, Keefe DM, Peterson DE. Role of cyclooxygenase pathway in chemotherapy induced oral mucositis: a pilot study. *Support care cancer* 2010; 18; 95-103
8. Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT. Chemotherapy induces the expression of COX-2 in non-small cell lung cancer. *Clin Cancer Res* 2005;11:4191-97
9. Chen YM, Peng JW, Liu JM, Kuo BI. Serum cytokine level fluctuations in chemotherapy-induced myelosuppression. *Japan J Clin Oncology* 1996; 26 (1) : 18-23
10. Hofer M, Pospisil M, Znojil V, Holá J, Vacek A, Streitová D. Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy. *Physiol Res* 2008; 57: 307-10
11. Hofer M, Pospisil M, Znojil V, Holá J, Vacek A, Weiterová L, et al. Meloxicam, a cyclooxygenase 2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. *Radiation Res* 2006; 166(3): 556-60
12. Salome J, Stanford, Pepper JR, Mitchell JA. COX-2 regulates GM-CSF, but not IL-8, production by human vascular cells. *Arterioscler Thromb Vasc Biol.* 2000; 20: 677-82
13. Hofer M, Pospisil M, Znojil V, Holá J, Vacek A, Streitová D. Meloxicam elevates serum concentration of erythropoietin and number of bone marrow erythroid progenitor cells in sublethally gamma irradiated mice. *Acta Vet. Brno.* 2009; 78: 19-22

14. Ibelgaufts H. G-CSF. COPE : Cytokines and cells online pathfinder encyclopedia. Available at <http://www.copewithcytokines.de/cope.cgi?key=G-CSF>. Cited at October 23rd, 2011
15. Hofer M, Pospisil M. Stimulated recovery of preturbed haematopoiesis by inhibition of prostaglandin production-promising therapeutic strategy. *Central Eur J of Biol* 2006;1:584-93
16. Lazzeri N, Belvisi MG, Patel HJ, Yacoub MH, Chung KF, Mitchell JA. Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. *Am J. Respir. Cell Mol. Biol* 2001;24:44-8
17. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of GCSF to reduce the incidence of FN in adult patients with lymphomas and solid tumours. *Eur J Cancer* 2006; 42(15): 2433-53
18. EONS. G-CSF in neutropenia guidelines. Available at <http://www.cancernurse.eu/documents/EONSClinicalGuidelinesSection3-en.pdf>. Cited at October 23rd, 2011
19. Abbas AK, Lichtman AH, Pober JS. *Cellular and molecular immunology*. 5th Ed. WB. Saunders Company: Philadelphia, 2007:p94-7,177-9
20. Constantinides P. *General Pathobiology*. Connecticut: Appleton & Lange, 1994:p1-34
21. Baretta G. *Cancer Treatment Medical Guide*. 10th ed. Milan (Italy): Farmitalia Carlo Erba-Erbamont; 1991:p1-58

22. Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials in oncology. *The Oncologist* 2009; 14:6-15
23. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. *Blood J* 2002; 100:3457-69
24. NCCN. Myeloid growth factor in cancer treatment v.1. 2010. Available at www.nccn.com. Last updated 12/07/09. Cited at October 23rd, 2011
25. Adam JR, Angelotta C, Bennet CR. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?. *J of Clin Oncology* 2006; 24: 2975-7
26. Molineux G, Dexter TM. Biology of G-CSF. In : Dexter TM. *Filgrastim in clinical practice* 2nd Ed. London. Informa Healthcare 1998; p1-39
27. Meloxicam official FDA information, side effects, and uses". *Drugs.com*. March 2010. Cited at October 23rd, 2011
28. European Medicines Agency Veterinary Medicines and Inspections. MELOXICAM (Extrapolation to rabbits and goats). 2006. Available at <http://www.emea.europa.eu>. Cited at October 23rd, 2011
29. Bernard MP, Bancos S, Sime PJ. Targeting COX2 in hematological malignancies : rational and promise. *Curr Pharm* 2008; 14(21): 2051-60
30. Khoo KS, Ang PT. Extract of astragalus membranaceus and kigustrum lucidum does not prevent cyclophosphamide-induced myelosuppression. *Singapore Med J*.1995;36(4):387-90

31. Li Y, Praseedom MK, Butler A, Zhou L, Yang Y. Cyclooxygenase-2 Inhibitor and gastric cancer. In: Howardell MJ. COX-2 Inhibitor Research. New York. Nova Sci. Pub 2006;p.1-83
32. Blanke CD, Masferrer JL. Chemotherapy with Cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials. *Prog Exp Tum Res. Basel, Karger* 2003; 37: 243–60
33. Sarjadi. Karsinoma epidermoid serviks uteri (Beberapa aspek epidemiologi serta peran histopatologi dan petanda tumor dalam penentuan prognosis). Disertasi doctor. Semarang. Universitas Diponegoro 1985: 112-4
34. Baratawidjaja KG. *Imunologi dasar*. Edisi 6. Balai penerbit FK UI; 2004
35. Theml H, Diem H, Haferlach T. *Color atlas of hematology practical microscopic and clinical diagnosis*. 2nd ed. Georg Thieme Verlag. 2004; p39,51
36. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patient with cancer. *Clin Infect Dis* 2002;34; 730-51
37. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of GCSF to reduce the incidence of FN in adult patients with lymphomas and solid tumours. *Eur J Cancer* 2006; 42(15): 2433-53
38. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents

FN in patients with breast cancer: a multicenter, double-blind, placebo controlled phase III study. *J Clin Oncol.* 2005;23:1178-84

39. Lyman GH, Crawford J. Cancer supportive care : Advances in therapeutic strategies. New York. Informa Healthcare. 2008 : 59-72; 135 – 48.

40. Sharp PE, Regina MC. The laboratory rat. Florida. CRC Press. 1998;p29